All In Biotech

NDA 204684 · Eton

Impavido

Miltefosine · Oral · Antileishmanial

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 19, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

42

15 Phase 3, 2 recruiting

FAERS reports

388

377 serious, 121 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 3, 2026.

IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials (14.1)]. • Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials (14.2)]. • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials (14.3)]. Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials (14.1, 14.2)]. • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials (14.1, 14.2)]. • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. IMPAVIDO is an antileishmanial drug indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis due to Leishmania donovani (1). • Cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis , and Leishmania panamensis (1). • Mucosal leishmaniasis due to Leishmania braziliensis (1). Limitations of use Leishmania species evaluated in clinical trials were based on epidemiologic data. There may be geographic variation in the response of the same Leishmania species to IMPAVIDO (1, 14). The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 19, 2014 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • IMPAVIDO · MILTEFOSINE 50MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Miltefosine" as an intervention, any sponsor and status, largest first.

All 42 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use122
  • drug ineffective109
  • nausea59
  • drug ineffective for unapproved indication57
  • condition aggravated33
  • vomiting33
  • product use in unapproved indication26
  • disease recurrence24
  • decreased appetite22
  • visceral leishmaniasis20
  • renal failure18
  • acute kidney injury17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20061
20071
20092
20101
20115
20134
201416
201511
20168
201723
201829
201931
202032
202146
202227
202331
202432
202558
202629

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Impavido (Miltefosine)

2024 spending

$1.5M

Beneficiaries

20

32 claims

Per beneficiary

$74,009

$598.05 per unit

View as table
YearSpending
2020$941,083
2021$800,566
2022$1,283,054
2023$1,649,352
2024$1,480,172

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 120 on PubMed

Sponsor: Eton

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.